Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$69.76 +1.7%	$9.82	$4.77 ▼ $72.90	$4.35B	0.33	2.23 million shs	8.33 million shs
AUTL Autolus Therapeutics	$2.64 -1.5%	$2.12	$1.11 ▼ $5.00	$713.26M	1.81	1.39 million shs	2.86 million shs
ENTA Enanta Pharmaceuticals	$7.34 -5.0%	$7.04	$4.09 ▼ $15.92	$165.24M	0.84	170,832 shs	93,488 shs
XNCR Xencor	$9.24 -3.4%	$8.57	$7.16 ▼ $27.24	$681.10M	0.85	629,010 shs	493,665 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+586.00%	+594.33%	+1,022.75%	+889.90%	+469.77%
AUTL Autolus Therapeutics	+2.68%	+9.84%	+21.27%	+91.43%	-37.53%
ENTA Enanta Pharmaceuticals	+0.78%	+9.03%	+8.57%	+36.33%	-48.43%
XNCR Xencor	+4.02%	+8.38%	+13.79%	-11.72%	-51.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVX Abivax	2.7036 of 5 stars	3.6	2.0	0.0	3.7	0.8	0.6
AUTL Autolus Therapeutics	2.7261 of 5 stars	3.5	1.0	0.0	2.4	3.3	0.6
ENTA Enanta Pharmaceuticals	3.9152 of 5 stars	3.4	1.0	4.7	2.8	2.5	0.0
XNCR Xencor	4.119 of 5 stars	3.4	5.0	3.9	0.0	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	3.11	Buy	$80.00	14.68% Upside
AUTL Autolus Therapeutics	3.00	Buy	$9.32	253.03% Upside
ENTA Enanta Pharmaceuticals	2.80	Moderate Buy	$18.00	145.23% Upside
XNCR Xencor	2.75	Moderate Buy	$28.00	203.03% Upside

Current Analyst Ratings Breakdown

Latest ENTA, AUTL, XNCR, and ABVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2025	ABVX Abivax	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$74.00
7/23/2025	ABVX Abivax	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$45.00 ➝ $101.00
7/23/2025	ABVX Abivax	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$42.00 ➝ $70.00
7/23/2025	ABVX Abivax	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $101.00
7/23/2025	ABVX Abivax	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$71.00
7/23/2025	ABVX Abivax	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $95.00
7/21/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/18/2025	ABVX Abivax	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$33.00
7/18/2025	ABVX Abivax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/3/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$23.00 ➝ $24.00

(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$0.69 per share	N/A
AUTL Autolus Therapeutics	$10.12M	69.43	N/A	N/A	$1.61 per share	1.64
ENTA Enanta Pharmaceuticals	$67.64M	2.32	N/A	N/A	$6.08 per share	1.21
XNCR Xencor	$110.49M	5.95	N/A	N/A	$9.63 per share	0.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$190.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/11/2025 (Estimated)
AUTL Autolus Therapeutics	-$220.66M	-$0.88	N/A	N/A	N/A	N/A	-52.82%	-29.67%	8/14/2025 (Estimated)
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.54	N/A	N/A	N/A	-149.57%	-79.83%	-26.65%	8/4/2025 (Estimated)
XNCR Xencor	-$232.62M	-$3.06	N/A	N/A	N/A	-181.17%	-31.94%	-22.19%	8/4/2025 (Estimated)

Latest ENTA, AUTL, XNCR, and ABVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.2329	N/A	N/A	N/A	$12.92 million	N/A
8/11/2025	Q2 2025	ABVX Abivax	-$0.9220	N/A	N/A	N/A	$1.19 million	N/A
8/4/2025	Q3 2025	ENTA Enanta Pharmaceuticals	-$1.10	N/A	N/A	N/A	$16.21 million	N/A
8/4/2025	Q2 2025	XNCR Xencor	-$0.78	N/A	N/A	N/A	$22.59 million	N/A
5/12/2025	Q2 2025	ENTA Enanta Pharmaceuticals	-$1.04	-$1.06	-$0.02	-$1.06	$15.96 million	$14.93 million
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million
5/8/2025	Q1 2025	XNCR Xencor	-$0.60	-$0.66	-$0.06	-$0.66	$23.44 million	$32.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	1.29	1.25	1.25
AUTL Autolus Therapeutics	N/A	9.24	9.02
ENTA Enanta Pharmaceuticals	N/A	5.29	5.29
XNCR Xencor	0.16	5.89	5.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
AUTL Autolus Therapeutics	72.83%
ENTA Enanta Pharmaceuticals	94.99%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
AUTL Autolus Therapeutics	25.70%
ENTA Enanta Pharmaceuticals	13.89%
XNCR Xencor	4.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	61	63.47 million	N/A	Not Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
ENTA Enanta Pharmaceuticals	160	21.38 million	18.41 million	Optionable
XNCR Xencor	280	71.17 million	67.78 million	Optionable

ENTA, AUTL, XNCR, and ABVX Headlines

Recent News About These Companies

Xencor (NASDAQ:XNCR) Stock Price Down 4.3% - What's Next?

July 11, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Shares Pass Above 50 Day Moving Average - What's Next?

July 11, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Trading 7.3% Higher - What's Next?

July 9, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of "Moderate Buy" by Analysts

July 3, 2025 | marketbeat.com

Xencor, Inc. (XNCR) Latest Stock News & Headlines - Yahoo Finance

June 29, 2025 | ca.finance.yahoo.com

Insider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,215 Shares of Stock

June 17, 2025 | insidertrades.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)

May 13, 2025 | theglobeandmail.com

Xencor Reports First Quarter 2025 Financial Results

May 7, 2025 | uk.finance.yahoo.com

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

May 7, 2025 | zacks.com

Xencor, Inc. (NASDAQ:XNCR) EVP Nancy Valente Sells 4,616 Shares

May 7, 2025 | insidertrades.com

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

May 1, 2025 | zacks.com

William Blair starts Xencor stock with Outperform rating

April 23, 2025 | uk.investing.com

William Blair Initiates Coverage of Xencor (XNCR) with Outperform Recommendation

April 22, 2025 | msn.com

Xencor initiated with an Outperform at William Blair

April 21, 2025 | markets.businessinsider.com

Xencor participates in a conference call with JPMorgan

April 18, 2025 | markets.businessinsider.com

Xencor, Inc.: No Major Near Term Catalysts

April 11, 2025 | seekingalpha.com

Xencor (XNCR) Upgraded to Buy: Here's Why

April 10, 2025 | zacks.com

Xencor’s SWOT analysis: biotech stock faces pivotal year ahead

April 10, 2025 | uk.investing.com

Barclays Keeps Their Sell Rating on Xencor (XNCR)

April 3, 2025 | markets.businessinsider.com

The Court of Appeals for the Federal Circuit’s In Re Xencor Decision: Jepson Claims Require Written Description for Their Preambles

March 24, 2025 | jdsupra.com

Latest Federal Court Cases: In re: Xencor, Inc.

March 18, 2025 | jdsupra.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
3 Catalysts Driving Plug Power’s Turnaround Case
By Jeffrey Neal Johnson | July 18, 2025
View 3 Catalysts Driving Plug Power’s Turnaround Case
Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs
By Gabriel Osorio-Mazilli | July 11, 2025
View Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs
Snag These 3 Bargain Tech Stocks Before They Pop
By Gabriel Osorio-Mazilli | June 27, 2025
View Snag These 3 Bargain Tech Stocks Before They Pop
CAVA Group: Why the Growth Story Is Just Getting Started
By Jeffrey Neal Johnson | July 7, 2025
View CAVA Group: Why the Growth Story Is Just Getting Started

ENTA, AUTL, XNCR, and ABVX Company Descriptions

Abivax NASDAQ:ABVX

$69.76 +1.16 (+1.69%)

Closing price 04:00 PM Eastern

Extended Trading

$70.75 +0.99 (+1.42%)

As of 08:00 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Autolus Therapeutics NASDAQ:AUTL

$2.64 -0.04 (-1.49%)

Closing price 04:00 PM Eastern

Extended Trading

$2.64 0.00 (0.00%)

As of 06:52 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Enanta Pharmaceuticals NASDAQ:ENTA

$7.34 -0.39 (-5.05%)

Closing price 04:00 PM Eastern

Extended Trading

$7.34 0.00 (0.00%)

As of 07:47 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Xencor NASDAQ:XNCR

$9.24 -0.33 (-3.45%)

Closing price 04:00 PM Eastern

Extended Trading

$9.23 -0.01 (-0.11%)

As of 04:44 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time